Claims for Patent: 5,491,064

Summary for Patent: 5,491,064

Title:	HTS-1 gene, a human tumor suppressor gene
Abstract:	A gene which is associated with tumor suppression and is localized on chromosome 11 has now been identified. The identification, localization and sequence of a gene which demonstrates differential expression in a manner that correlates with tumorigenicity suggests that this gene could potentially be used for gene therapy in cancers deleted or altered in their expression of the gene. Furthermore, a gene which is localized on chromosome 11p15, with identified polymorphisms, could be used for analysis of tumor DNA for loss of heterozygosity at chromosome 11p15. This region of chromosome 11 shows frequent loss of heterozygosity (LOH) in many human malignancies. Thus, the determination of LOH at chromosome 11p15 may be useful in predicting the prognosis of that tumor.
Inventor(s):	Lichy; Jack H. (Silver Spring, MD), Howley; Peter M. (Potomac, MD)
Assignee:	The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	08/369,043
Patent Claims:	1. A purified nucleic acid having a sequence fully complementary to a nucleic acid of Sequence I.D. No. 1 said sequence binding specifically to sequence I.D. No. 1 and not to other human DNA sequences, when subject to 0.1.times. standard saline citrate buffer, 0.1% SDS at 65.degree. C. 2. A purified nucleic acid of claim 1 encoding the polypeptide of Sequence I.D. No. 2. 3. A purified nucleic acid of claim 1 which has a sequence of Sequence I.D. No. 1. 4. A purified nucleic acid of claim 1 having at least 12 continuous nucleotides. 5. A subsequence of the nucleic acid of claim 4, comprising bases 3570 to 4205 of Seq. I.D. No. 1. 6. A purified nucleic acid of claim 1, wherein a promoter is operably linked to the nucleic acid. 7. A nucleic acid of claim 6, wherein the promoter and the nucleic acid are contained in an expression vector. 8. A cell transformed or transfected with a nucleic acid of claim 1. 9. A cell of claim 8, wherein the cell is mammalian. 10. A cell transformed or transfected with a nucleic acid of claim 6. 11. A cell of claim 10, wherein the cell is mammalian. 12. A method of detecting the presence of the human tumor suppressor 1 gene in a physiological specimen, said method comprising; (i) contacting a nucleic acid probe which is at least 12 continuous nucleotides in length and is specific for binding to human tumor suppressor 1 gene with said specimen under conditions which allow said nucleic acid probe to anneal to complementary sequences in said sample; and (ii) detecting duplex formation between said nucleic acid probe and said complementary sequences. 13. A method of claim 12, wherein the nucleic acid probe of step (i) is a subsequence of the entire human tumor suppressor 1 gene. 14. A method of claim 12, wherein the specimen further comprises mRNA and the nucleic acid probe of step (i) is annealed to said mRNA. 15. A method of claim 14, wherein the mRNA is reverse transcribed to cDNA prior to annealing of the nucleic acid probe in step (i). 16. A method of claim 12, comprising in step (i) a second nucleic acid probe, further comprising multiple nucleic acid probes wherein two of the nucleic acid probes are PCR primers and further comprising between steps (i) and (ii), amplification of the human tumor suppressor 1 gene or subsequence thereof using PCR. 17. A method of claim 16, wherein PCR is used with the following set of primers: GACTGGCAGCGGGGACCTCA (Seq. I.D. No. 5) and AGCCAAACCACTGATCTTCC (Seq. I.D. No. 6). 18. A method of claim 12, wherein said physiological specimen is a member selected from the group consisting of human tissue, blood, and cells grown in culture. 19. A method of claim 12, further comprising the step of digesting the human tumor suppressor 1 gene with an endonuclease restriction enzyme prior to step (i). 20. A method of claim 12, wherein the nucleic acid probe binds to an intron found within the human tumor suppressor 1 gene. 21. A method of claim 12, wherein the nucleic acid probe comprises bases 305 to 2698 of Seq. I.D. No. 3. 22. A method of claim 12, wherein the nucleic acid probe has a sequence of Seq. I.D. No. 4.

Details for Patent 5,491,064

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	5,491,064	2015-01-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		5,491,064	2015-01-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		5,491,064	2015-01-05